In fiscal 2025, which ended Dec 31, 2025, BioNexus Gene Lab Corp. reported revenue of $7.4 million, down 21.9% from the year before. It recorded a net loss of $3.0 million. The operating loss came to $3.0 million, an operating margin of -39.9%. Over the twelve months ended Jun 30, 2026, revenue was $3.1 million and the net loss was $2.6 million. Across the 7 fiscal years shown, revenue grew from $126,955 in fiscal 2019 to $7.4 million in fiscal 2025, about 97.0% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
|---|---|---|---|---|---|---|---|---|
| Revenue |
3
-67.3%
|
7
-21.9%
|
10
-2.7%
|
10
-10.6%
|
11
-18.2%
|
13
+17.3%
|
11
+8872.0%
|
0
|
| Cost of revenue |
3
-66.6%
|
6
-22.9%
|
8
-2.6%
|
8
-12.7%
|
10
-12.9%
|
11
+14.7%
|
10
+13507.7%
|
0
|
| Gross profit |
0
-71.4%
|
1
-15.8%
|
1
-3.0%
|
1
+5.6%
|
1
-44.5%
|
2
+31.8%
|
2
+2977.3%
|
0
|
| Research and development |
0
|
0
+6.6%
|
0
|
—
|
—
|
—
|
—
|
—
|
| Selling, general and administrative |
2
+3.3%
|
3
-15.3%
|
4
+58.2%
|
2
+41.2%
|
2
+35.4%
|
1
-4.2%
|
1
+273.7%
|
0
|
| Operating income |
-3
+14.3%
|
-3
-88.4%
|
-2
+39.3%
|
-3
-790.7%
|
-0
-127.6%
|
1
-17.1%
|
1
+562.0%
|
-0
|
| Pretax income |
-3
+14.3%
|
-3
-87.1%
|
-2
+38.8%
|
-3
-758.7%
|
-0
|
—
|
—
|
—
|
| Income tax |
0
+100.0%
|
0
+100.0%
|
-0
+83.8%
|
-0
+58.8%
|
-0
|
—
|
—
|
0
|
| Net income |
-3
+12.2%
|
-3
-86.7%
|
-2
+39.2%
|
-3
-638.6%
|
-0
-147.4%
|
1
-31.3%
|
1
+543.9%
|
-0
|
| Diluted EPS |
—
|
—
|
-0.09
|
—
|
—
|
—
|
—
|
—
|
| Weighted average shares, diluted |
—
|
—
|
18
|
—
|
—
|
—
|
—
|
—
|
| Other measures | ||||||||
| Depreciation and amortization |
0
-3.8%
|
0
+7.4%
|
0
+25.1%
|
0
-8.9%
|
0
+0.2%
|
0
+0.5%
|
0
+117.6%
|
0
|
| EBITDA |
-2
+14.7%
|
-3
-94.2%
|
-1
+41.5%
|
-3
-1156.7%
|
-0
-117.4%
|
1
-15.9%
|
1
+683.2%
|
-0
|
| Interest coverage |
—
|
—
|
—
|
-186.20x
|
—
|
—
|
—
|
—
|
| Margins | ||||||||
| Gross margin |
12.34%
|
14.62%
|
13.56%
|
13.61%
|
11.52%
|
16.96%
|
15.10%
|
44.02%
|
| Operating margin |
-81.82%
|
-39.93%
|
-16.55%
|
-26.54%
|
-2.66%
|
7.90%
|
11.18%
|
-217.17%
|
| Pretax margin |
-82.36%
|
-40.20%
|
-16.77%
|
-26.69%
|
-2.78%
|
—
|
—
|
—
|
| Profit margin |
-82.36%
|
-40.20%
|
-16.81%
|
-26.91%
|
-3.26%
|
5.62%
|
9.61%
|
-194.14%
|
| EBITDA margin |
-78.18%
|
-38.43%
|
-15.45%
|
-25.69%
|
-1.83%
|
8.58%
|
11.98%
|
-184.31%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- BGLC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- WY
- Headquarters
- Kuala Lumpur
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1737523
- Former names
- BioNexus Gene Lab Coporation (until May 8, 2020)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.